1017 related articles for article (PubMed ID: 21491413)
21. Gemcitabine Plus Cisplatin Split
Izumi K; Iwamoto H; Yaegashi H; Shigehara K; Nohara T; Kadono Y; Mizokami A
In Vivo; 2019; 33(1):167-172. PubMed ID: 30587618
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine/cisplatin versus methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive bladder cancer: A systematic review and meta-analysis.
Yu C; Hequn C; Jinbo C; Feng Z; Xiongbing Z; Jian D
J Cancer Res Ther; 2018; 14(6):1260-1265. PubMed ID: 30488841
[TBL] [Abstract][Full Text] [Related]
23. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C; Gravis G; Flechon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Soulie M; Allory Y; Harter V; Culine S;
Lancet Oncol; 2024 Feb; 25(2):255-264. PubMed ID: 38142702
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.
Bellmunt J; Albiol S; de Olano AR; Pujadas J; Maroto P;
Ann Oncol; 2006 May; 17 Suppl 5():v113-7. PubMed ID: 16807437
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Halim A; Abotouk N
Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
[TBL] [Abstract][Full Text] [Related]
26. Systemic chemotherapy of transitional cell carcinoma of the urothelium.
Brinkley WM; Torti FM
Semin Surg Oncol; 1997; 13(5):365-75. PubMed ID: 9259093
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
28. Progress in the management of metastatic bladder cancer.
Parimoo D; Raghavan D
Cancer Control; 2000; 7(4):347-56. PubMed ID: 10895129
[TBL] [Abstract][Full Text] [Related]
29. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
Lee Y; Kim YS; Hong B; Cho YM; Lee JL
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3421-3429. PubMed ID: 33715088
[TBL] [Abstract][Full Text] [Related]
30. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
[TBL] [Abstract][Full Text] [Related]
31. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Oing C; Rink M; Oechsle K; Seidel C; von Amsberg G; Bokemeyer C
J Urol; 2016 Feb; 195(2):254-63. PubMed ID: 26410730
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine in advanced bladder cancer.
von der Maase H
Semin Oncol; 2001 Apr; 28(2 Suppl 7):11-4. PubMed ID: 11372046
[TBL] [Abstract][Full Text] [Related]
33. New approaches to treatment of metastatic bladder cancer.
Edelman MJ
Curr Oncol Rep; 2000 Sep; 2(5):379-85. PubMed ID: 11122868
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine doublets in advanced urothelial cancer.
Stadler WM
Semin Oncol; 2002 Feb; 29(1 Suppl 3):15-9. PubMed ID: 11894003
[TBL] [Abstract][Full Text] [Related]
35. [Gemcitabine in advanced bladder cancer].
Lehmann J; Retz M; Lippert C; Albers P; Stöckle M
Urologe A; 2003 Jan; 42(1):63-77. PubMed ID: 12574885
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine in the treatment of bladder cancer.
Ryan CW; Vogelzang NJ
Expert Opin Pharmacother; 2000 Mar; 1(3):547-53. PubMed ID: 11249537
[TBL] [Abstract][Full Text] [Related]
37. Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes.
Ichioka D; Miyazaki J; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Nishiyama H
Jpn J Clin Oncol; 2015 Sep; 45(9):867-73. PubMed ID: 26056328
[TBL] [Abstract][Full Text] [Related]
38. [Gemcitabine and cisplatin therapy in advanced or metastatic urothelial cancer: comparison of side effect with MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)].
Ochi T; Ozawa A; Tanji N; Yanagihara Y; Yanagaki T; Miyauchi Y; Ikeda T; Shimamoto K; Toshino A; Sugawara T; Hamada H; Yokoyama M
Nihon Hinyokika Gakkai Zasshi; 2006 Sep; 97(6):777-81. PubMed ID: 17025209
[TBL] [Abstract][Full Text] [Related]
39. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Sternberg CN; Skoneczna I; Kerst JM; Albers P; Fossa SD; Agerbaek M; Dumez H; de Santis M; Théodore C; Leahy MG; Chester JD; Verbaeys A; Daugaard G; Wood L; Witjes JA; de Wit R; Geoffrois L; Sengelov L; Thalmann G; Charpentier D; Rolland F; Mignot L; Sundar S; Symonds P; Graham J; Joly F; Marreaud S; Collette L; Sylvester R; ; ; ; ;
Lancet Oncol; 2015 Jan; 16(1):76-86. PubMed ID: 25498218
[TBL] [Abstract][Full Text] [Related]
40. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).
De Santis M; Wiechno PJ; Bellmunt J; Lucas C; Su WC; Albiges L; Lin CC; Senkus-Konefka E; Flechon A; Mourey L; Necchi A; Loidl WC; Retz MM; Vaissière N; Culine S
Ann Oncol; 2016 Mar; 27(3):449-54. PubMed ID: 26673352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
